Close Menu

NEW YORK – New drugs are more likely to be approved if they target a gene linked to disease, according to a new analysis from AbbVie researchers that confirms earlier findings. 

Only between 5 percent and 10 percent of new drug candidates that enter early-stage clinical trials are eventually approved. In 2015, researchers led by GlaxoSmithKline's Philippe Sanseau reported that drugs with supporting genetic evidence were twice as likely to be approved.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.

Oct
06
Sponsored by
10x Genomics

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by irreversible scarring of the distal lung, leading to respiratory failure. 

Oct
13
Sponsored by
Lexogen

This webinar will outline the use of targeted protein degradation (TPD) to understand transcriptional processes at a high kinetic resolution.